Molly A. Nelson

465 total citations · 1 hit paper
8 papers, 349 citations indexed

About

Molly A. Nelson is a scholar working on Oncology, Immunology and Biomedical Engineering. According to data from OpenAlex, Molly A. Nelson has authored 8 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Immunology and 4 papers in Biomedical Engineering. Recurrent topics in Molly A. Nelson's work include Cancer Immunotherapy and Biomarkers (4 papers), Nanoplatforms for cancer theranostics (4 papers) and Nanoparticle-Based Drug Delivery (2 papers). Molly A. Nelson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Nanoplatforms for cancer theranostics (4 papers) and Nanoparticle-Based Drug Delivery (2 papers). Molly A. Nelson collaborates with scholars based in United States, Canada and Thailand. Molly A. Nelson's co-authors include Worapol Ngamcherdtrakul, Wassana Yantasee, Shiuh‐Wen Luoh, Ruijie Wang, Daniel S. Bejan, Moataz Reda, Joe W. Gray, Gordon B. Mills, Ngoc Ha Hoang and Natnaree Siriwon and has published in prestigious journals such as Advanced Materials, Nature Communications and Cancer Research.

In The Last Decade

Molly A. Nelson

8 papers receiving 345 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

2022 140 citations Moataz Reda, Worapol Ngamcherdtrakul et al. Nature Communications profile →

Peers

Countries citing papers authored by Molly A. Nelson

Since Specialization

Citations

This map shows the geographic impact of Molly A. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly A. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly A. Nelson more than expected).

Fields of papers citing papers by Molly A. Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly A. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly A. Nelson. The network helps show where Molly A. Nelson may publish in the future.

Co-authorship network of co-authors of Molly A. Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Molly A. Nelson. A scholar is included among the top collaborators of Molly A. Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly A. Nelson. Molly A. Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	A lack of commensal microbiota influences the male reproductive tract intergenerationally in mice 2025 ·Reproduction ·Natalie A. Trigg, (unknown), (unknown), (unknown), Molly A. Nelson, Michael A. Silverman, Taku Kambayashi, Colin C. Conine	2
2	Abstract 3229: Triggering anti-tumor immune response with a nanotherapeutic that targets TLR9 and STAT3 pathways 2023 ·Cancer Research ·Worapol Ngamcherdtrakul, Moataz Reda, (unknown), (unknown), Ruijie Wang, (unknown), (unknown), (unknown), (unknown), (unknown), Molly A. Nelson, Joe W. Gray, Wassana Yantasee	1
3	Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis 2022 ·Small ·Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, (unknown), Natnaree Siriwon, (unknown), Ruijie Wang, Molly A. Nelson, (unknown), Joe W. Gray, Kullervo Hynynen, Wassana Yantasee	42
4	Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment breakdown → 2022 ·Nature Communications ·Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, (unknown), Daniel S. Bejan, (unknown), Ngoc Ha Hoang, (unknown), (unknown), (unknown), Gordon B. Mills, Joe W. Gray, Wassana Yantasee	140
5	Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022) 2022 ·Small ·Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, (unknown), Natnaree Siriwon, (unknown), Ruijie Wang, Molly A. Nelson, (unknown), Joe W. Gray, Kullervo Hynynen, Wassana Yantasee	1
6	In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response 2021 ·Advanced Materials ·Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson, Ruijie Wang, (unknown), Daniel S. Bejan, Ngoc Ha Hoang, Ryan S. Lane, Shiuh‐Wen Luoh, Sancy A. Leachman, Gordon B. Mills, Joe W. Gray, Amanda W. Lund, Wassana Yantasee	61
7	Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer 2021 ·Cancer and Metastasis Reviews ·Molly A. Nelson, Worapol Ngamcherdtrakul, Shiuh‐Wen Luoh, Wassana Yantasee	78
8	Dyskeratosis congenita Haematologic, cytogenetic, and dermatologic studies 1984 ·Scandinavian Journal of Haematology ·Peter Jacobs, Norma Saxe, (unknown), Molly A. Nelson	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact